UniProt Q92630 · PDB · AlphaFold · Substrate: DYRKtide · Clone: full lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Abemaciclib | 97.1% | 2.9% | 91.48 | 0.563 |
| 2 | Selpercatinib | 75.9% | 24.1% | 96.72 | 0.635 |
| 3 | Defactinib | 74.8% | 25.2% | 92.68 | 0.450 |
| 4 | Afatinib | 62.6% | 37.4% | 98.50 | 0.709 |
| 5 | Osimertinib | 62.1% | 37.9% | 97.24 | 0.733 |
| 6 | Palbociclib | 53.2% | 46.8% | 98.75 | 0.673 |
| 7 | Dacomitinib | 52.1% | 47.9% | 97.99 | 0.664 |
| 8 | Ponatinib | 51.5% | 48.5% | 78.23 | 0.534 |
| 9 | Pacritinib | 46.0% | 54.0% | 88.64 | 0.452 |
| 10 | Sunitinib | 37.2% | 62.8% | 91.73 | 0.524 |
| 11 | Avapritinib | 36.8% | 63.2% | 97.73 | 0.644 |
| 12 | Crizotinib | 35.9% | 64.1% | 91.39 | 0.581 |
| 13 | Midostaurin | 35.6% | 64.4% | 78.64 | 0.500 |
| 14 | Brigatinib | 34.4% | 65.6% | 82.96 | 0.513 |
| 15 | Erlotinib | 29.6% | 70.4% | 99.75 | 0.695 |
| 16 | Gefitinib | 28.8% | 71.2% | 99.25 | 0.650 |
| 17 | Netarsudil | 27.6% | 72.4% | 93.22 | 0.676 |
| 18 | Gilteritinib | 27.5% | 72.5% | 88.97 | 0.506 |
| 19 | Canertinib | 26.1% | 73.9% | 96.49 | 0.671 |
| 20 | Neratinib | 23.6% | 76.4% | 93.18 | 0.597 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 3.64
- Epithelial log2(TPM+1): 3.44
- Fold change: 0.21
- Status: No significant change
High-confidence drugs
- Abemaciclib — inh 97.1% · KISS 34.32
- Selpercatinib — inh 75.9% · KISS 18.45
- Afatinib — inh 62.6% · KISS 9.89
Selectivity landscape vs inhibition on DYRK2
Each point is one of the 92 approved drugs; color = inhibition % on DYRK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…